Adrenal insufficiency is a contraindication for omalizumab therapy in mast cell activation disease: risk for serum sickness
Molderings, G. J., Dumoulin, F. L., Homann, J., Sido, B., Textor, J., Mücke, M., Qagish, G. J., Barion, R., Raithel, M., Klingmüller, D., Schäfer, V. S., Hertfelder, H. J., Berdel, D., Tridente, G.Journal:
Naunyn-Schmiedeberg's Archives of Pharmacology
DOI:
10.1007/s00210-020-01886-2
Date:
May, 2020
File:
PDF, 371 KB
2020
File converter
More search results
More benefits 
